Natsuki Ito, Takahiro Kudo, Hidetaka Eguchi, Keisuke Jimbo, Yasushi Okazaki, Toshiaki Shimizu et al. Anti-TNF–refractory inflammatory bowel disease associated with a novel XIAP frameshift variant successfully treated with ustekinumab. // Clinical Journal of Gastroenterology. – 2026. – DOI: 10.1007/s12328-026-02394-1. – URL: https://doi.org/10.1007/s12328-026-02394-1
Natsuki Ito, Takahiro Kudo, Hidetaka Eguchi, Keisuke Jimbo, Yasushi Okazaki, Toshiaki Shimizu, & Hiromichi Shoji (2026). Anti-TNF–refractory inflammatory bowel disease associated with a novel XIAP frameshift variant successfully treated with ustekinumab. Clinical Journal of Gastroenterology. https://doi.org/10.1007/s12328-026-02394-1
Natsuki Ito, et al. “Anti-TNF–refractory inflammatory bowel disease associated with a novel XIAP frameshift variant successfully treated with ustekinumab.” Clinical Journal of Gastroenterology, 2026. doi:10.1007/s12328-026-02394-1.
@article{Ito2026,
title = {Anti-TNF–refractory inflammatory bowel disease associated with a novel XIAP frameshift variant successfully treated with ustekinumab},
author = {Ito, Natsuki and Kudo, Takahiro and Eguchi, Hidetaka and Jimbo, Keisuke and Okazaki, Yasushi and Shimizu, Toshiaki and Shoji, Hiromichi},
journal = {Clinical Journal of Gastroenterology},
year = {2026},
doi = {10.1007/s12328-026-02394-1},
url = {https://doi.org/10.1007/s12328-026-02394-1}
}